Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Dives Into Biomedical Innovation: Will It Drown In A Deep Sea Of Competing Needs?

Executive Summary

House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.

You may also be interested in...



Real-World Evidence, Digital Health, Insurance Coverage Reforms On Cures 2.0 Agenda

All three areas need work following enactment of the original 21st Century Cures Act, authors Fred Upton and Diana DeGette write in vision statement.

FDA’s Top Two Reform Priorities Aren’t Really Legislative Material

Senate eyes a biomedical reform process that is simultaneously narrower and slower than the House’s 21st Century Cures Initiative; FDA’s Hamburg asks for ability to shape sponsor’s trial designs earlier and more regulatory science funding.

Cost Of FDA Reforms Is Big Challenge For ‘Cures’ Legislation

Drug industry warns that unfunded mandates in the 21st Century Cures discussion document could impact FDA’s ability to focus on drug reviews; Energy and Commerce legislators are working to get appropriators on board.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel